If your favorite internet doctor seems to have a weirdly intense vendetta against compounded or non-branded GLP-1s, a new Washington Post investigation may help explain part of the environment they are operating in. The paper found Eli Lilly and Novo Nordisk spent more than $270 million promoting their diabetes and obesity drugs since 2018, with payment…
If Your Favorite Internet Doctor Has a Weird Vendetta Against Non-Branded GLP-1s, This May Help Explain Why
Keep reading with a 7-day free trial
Subscribe to ON THE PEN to keep reading this post and get 7 days of free access to the full post archives.